The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
The effect of deprenyl and levodopa on the progression of Parkinson's disease
Abstract
We have performed a 14‐month, prospective, randomized, double‐blind, placebo‐controlled study to evaluate the effect of deprenyl and levodopa/carbidopa (Sinemet) on the progression of signs and symptoms in patients with mild Parkinson's disease (PD). One hundred one untreated PD patients were randomly assigned to one of the following four treatment groups: Group I, deprenyl + Sinemet; Group II, placebo‐deprenyl + Sinemet; Group III, deprenyl + bromocriptine; and Group IV, placebo‐deprenyl + bromocriptine. The final visit was performed at 14 months, i.e., 2 months after withdrawal of deprenyl or its placebo and 7 days after withdrawal of Sinemet or bromocriptine. Deterioration in Unified Parkinson's Disease Rating Score (UPDRS) between untreated baseline and final visits was used as an index of disease progression. Placebo‐treated patients deteriorated by 5.8 ± 1.4 points, while deprenyl‐treated patients deteriorated by 0.4 ± 1.3 points (p < 0.001). This effect was sufficiently powerful that a significant deprenyl effect could be detected in the subgroup of 41 patients randomized to Sinemet (p < 0.01) as well as in the 23 patients who completed a 14‐day washout of Sinemet or bromocriptine (p < 0.05). No difference in the extent of deterioration was detected in patients randomized to Sinemet versus bromocriptine. This study demonstrates that deprenyl attenuates deterioration in UPDRS score in patients with early PD. These findings are not readily explained by the drug's symptomatic effects and are consistent with the hypothesis that deprenyl has a neuroprotective effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J. P., Deng, H.-X., et al. (1993) · Nature · doi:10.1038/362059a0 · Cited by 7,062
Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K., & Seitelberger, F. (1973) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(73)90175-5 · Cited by 2,651
Mitochondrial Complex I Deficiency in Parkinson's Disease
Schapira, A. H. V., Cooper, J. M., Dexter, D., Clark, J. B., Jenner, P., & Marsden, C. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb02325.x · Cited by 2,283
Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease
Dexter, D. T., Carter, C. J., Wells, F. R., Javoy‐Agid, F., Agid, Y., Lees, A., Jenner, P., & Marsden, C. D. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb09133.x · Cited by 1,397
Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains
Riederer, P., Sofic, E., Rausch, W., Schmidt, B., Reynolds, G. P., Jellinger, K., & Youdim, M. B. H. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb09150.x · Cited by 1,383
Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
(1993) · New England Journal of Medicine · doi:10.1056/nejm199301213280305 · Cited by 1,221
Dexter, D. T., Wells, F. R., Lee, A. J., Agid, F., Agid, Y., Jenner, P., & Marsden, C. D. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb07264.x · Cited by 1,149
Effect of Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198911163212004 · Cited by 917
Oxygen radicals and the nervous system
Halliwell, B., & Gutteridge, J. M. C. (1985) · Trends in Neurosciences · doi:10.1016/0166-2236(85)90010-4 · Cited by 819
Parkinson's disease: A disorder due to nigral glutathione deficiency?
Perry, T. L., Godin, D. V., & Hansen, S. (1982) · Neuroscience Letters · doi:10.1016/0304-3940(82)90390-1 · Cited by 753
Deficiencies in Complex I subunits of the respiratory chain in Parkinson's disease
Mizuno, Y., Ohta, S., Tanaka, M., Takamiya, S., Suzuki, K., Sato, T., Oya, H., Ozawa, T., & Kagawa, Y. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)91141-8 · Cited by 739
A radical hypothesis for neurodegeneration
Olanow, C. W. (1993) · Trends in Neurosciences · doi:10.1016/0166-2236(93)90070-3 · Cited by 722
Self-citationThe Effect of Deprenyl (Selegiline) on the Natural History of Parkinson's Disease
Tetrud, J. W., & Langston, J. W. (1989) · Science · doi:10.1126/science.2502843 · Cited by 638
Compensations after lesions of central dopaminergic neurons: some clinical and basic implications
Zigmond, M. J., Abercrombie, E. D., Berger, T. W., Grace, A. A., & Stricker, E. M. (1990) · Trends in Neurosciences · doi:10.1016/0166-2236(90)90112-n · Cited by 609
Selective Increase of Iron in Substantia Nigra Zona Compacta of Parkinsonian Brains
Sofic, E., Paulus, W., Jellinger, K., Riederer, P., & Youdim, M. B. H. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb02017.x · Cited by 524
Good, P. F., Olanow, C. W., & Perl, D. P. (1992) · Brain Research · doi:10.1016/0006-8993(92)91334-b · Cited by 427
Self-citationAn introduction to the free radical hypothesis in Parkinson's disease
Olanow, C. W. (1992) · Annals of Neurology · doi:10.1002/ana.410320703 · Cited by 382
Self-citationToxicity of 6‐hydroxydopamine and dopamine for dopaminergic neurons in culture
Michel, P. P., & Hefti, F. (1990) · Journal of Neuroscience Research · doi:10.1002/jnr.490260405 · Cited by 338
Cohen, G., Pasik, P., Cohen, B., Leist, A., Mytilineou, C., & Yahr, M. D. (1984) · European Journal of Pharmacology · doi:10.1016/0014-2999(84)90700-3 · Cited by 323
Youdim, M. B. H., Ben-Shachar, D., & Riederer, P. (1989) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1989.tb01782.x · Cited by 292
Rescue of dying neurons: A new action for deprenyl in MPTP parkinsonism
Tatton, W. G., & Greenwood, C. E. (1991) · Journal of Neuroscience Research · doi:10.1002/jnr.490300410 · Cited by 272
New insights into the cause of Parkinson's disease
Jenner, P., Schapira, A. H. V., & Marsden, C. D. (1992) · Neurology · doi:10.1212/wnl.42.12.2241 · Cited by 270
Oxidation reactions in Parkinson's disease.
Olanow, C. W. (1990) · PubMed · Cited by 245
Self-citationWu, R., Chiueh, C. C., Pert, A., & Murphy, D. L. (1993) · European Journal of Pharmacology · doi:10.1016/0014-2999(93)90181-g · Cited by 152
Quinn, N. P., Parkes, D., Janota, I., & MARSDEN, C. D. (1986) · Movement Disorders · doi:10.1002/mds.870010109 · Cited by 132
Perry, T. L., Yong, V. W., Ito, M., Foulks, J. G., Wall, R. A., Godin, D. V., & Clavier, R. M. (1984) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1984.tb12834.x · Cited by 130
Long‐term administration of L‐DOPA does not damage dopaminergic neurons in the mouse
Hefti, F. F., Melamed, E., Bhawan, J., & Wurtman, R. J. (1981) · Neurology · doi:10.1212/wnl.31.9.1194 · Cited by 126
Arnett, C. D., Fowler, J. S., MacGregor, R. R., Schlyer, D. J., Wolf, A. P., Långström, B., & Halldin, C. (1987) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1987.tb02895.x · Cited by 123
Exposure of striatal [corrected] synaptosomes to L-dopa increases levels of oxidized glutathione.
Spina, M. B., & Cohen, G. (1988) · PubMed · Cited by 77
A Rationale for Dopamine Agonists as Primary Therapy for Parkinson’s Disease
Olanow, C. W. (1992) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100041469 · Cited by 54
Self-citation
Cited by
Levodopa and the Progression of Parkinson's Disease
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa033447 · Cited by 1,821
ETIOLOGY AND PATHOGENESIS OF PARKINSON'S DISEASE
Olanow, C. W., & Tatton, W. G. (1999) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.22.1.123 · Cited by 1,396
Self-citationLang, A. E., & Lozano, A. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810153391607 · Cited by 1,201
The scientific and clinical basis for the treatment of Parkinson disease (2009)
Olanow, C. W., Stern, M. B., & Sethi, K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a1d44c · Cited by 908
Self-citationA Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
Olanow, C. W., Rascol, O., Hauser, R., Feigin, P. D., Jankovic, J., Lang, A., Langston, W., Melamed, E., Poewe, W., Stocchi, F., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809335 · Cited by 901
Self-citation
Metadata
- Authors
- Olanow, C. W., Hauser, R. A., Gauguster, L., Malapira, T., Koller, W., Hubble, J., Bushenbark, K., Lilienfeld, D., & Esterlitz, J.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 1995-11
- Volume
- 38
- Issue
- 5
- Pages
- 771-777
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2046712196
- Cited by
- 334
- References
- 30
- FWCI
- 15.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.